Robert Hollamby

Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom.

Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom.

Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom.

Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom.